Quality adjusted survival analysis is a new approach to therapy evaluation in clinical trials. It has received much attention recently because of its ability to take patients' quality of life into consideration. In this paper, we present a method that enables us to calculate the survival distribution of quality adjusted lifetime. Using martingale theory for counting processes, we can show that our estimator is asymptotically consistent, normally distributed, and its asymptotic variance estimate can be obtained analytically. Simulation experiments are conducted to compare our estimator with the true underlying distribution for two cases that are of practical importance.
INTRODUCTION
Quality adjusted survival analysis arises in treatment evaluation of chronic diseases, such as cancer or AIDS. Extending overall survival time may not be the only goal of a new therapy, since patients might have to endure longer time of toxicity from the drug; and life after disease recurrence might be painful. The concept of a quality adjusted life has received much attention recently, including an extensive review by Cox et al. (1992) . We present here a method for consistently estimating quality adjusted life, recognising that there is still debate on the use of such a simple measure.
Quality adjusted life has been studied by Gelber, German & Goldhirsch (1989) , Glasziou, Simes & Gelber (1990) , Goldhirsch et al. (1989) and Korn (1993) . Quality adjusted life places states of health on a utility scale with reference points ranging from 0 (death) to 1 (perfect health). The quality adjusted lifetime 'QAL' is given by U = £ q } S } , where q u ..., q k are the utility coefficients assigned to each of the 'k' health states, and Sj,..., S k are the times spent in each state. In a typical application, a patient undergoing treatment would first go through a period S lt where they would be subject only to toxicity, then at time S t + S 2 may have a relapse, and finally at time Si + S 2 + S 3 would die. A quality adjusted life measure, named Time Without Symptoms of disease and Toxicity 'TWIST' , is just equal to S 2 in this case. This is equivalent to setting quality of Life equal to 0 while a patient is either in the toxicity state or in a relapse state, and 1 while in the healthy state. One may set the quality of Life in these 'non-healthy states' to be values between 0 and 1. These values may depend on the disease, the treatment and the individual's own perception. For example, if quality of Life in the toxicity state is equated to ^ and in the relapse state to |, then quality adjusted Lifetime is U = ^S t + S 2 + 2S3 • This more general definition is called Quality adjusted Time Without Symptoms and Toxicity 'Q-T\viST' in the Literature.
In a typical clinical trial, patients enter the study over a period of time, and the study is terminated before all the information for every patient is observed. This results in varying amounts of follow-up and censored or incomplete quality adjusted survival time.
The question we address is how to draw inferences regarding the survival distribution of quality adjusted lifetime from such censored data.
One approach, use of the Kaplan-Meier estimator (Kaplan & Meier, 1958) with censored quality adjusted Life data, was shown by Gelber et al. (1989) to lead to biased estimation because of induced informative censoring. To our knowledge, no satisfactory method has been proposed for estimating the survival distribution for quality adjusted Lifetime. In this paper, we show how to construct an asymptotically unbiased, normally distributed estimator with variance that can be consistently estimated.
FORMALISATION OF THE PROBLEM
We first introduce some notation. For n individuals under study, let the ith individual's health history be described by a discrete-state continuous time stochastic process, {Vi(t), t ^ 0}, where V t (t) maps to the state space S = {0,1,..., k}; that is, at any time t, the health status V^t) can take on any of k + 1 values corresponding to different states of health. We shall assume that states 1,..., k are transient, whereas state '0' is absorbing. Thus, V t (s) = 0 implies Vi(t) = 0 for t ^ s. For example, in the definition of time without symptoms of disease and toxicity given previously, the toxicity state and the healthy state were transient, whereas 'relapse or death' considered as one combined state was absorbing. In the example of quality adjusted time without symptoms of disease and toxicity, the relapse state was also considered transient, whereas death was absorbing. Let Tf denote the time it takes the ith individual to move into the absorbing state '0': that is Tf = inf {t: ^(0 = 0}; Tf can be considered as the overall survival time. Define Q as a quality of life function mapping the state space S to the interval [0, 1] . In the problems that concern us, the functional form of Q is assumed to be known or can be specified, and we always make it equal to 0 for the absorbing state: that is g(0) = 0. With this notation, the ith individual's quality adjusted Lifetime is
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The ith individual also has a potential time to censoring denoted by Q > 0. The survival distribution function for C is given by K(u) = pr(C > u). In a cancer clinical trial, C, usually corresponds to the time from entry into the study until the time when analysis is performed, but it may be smaller because of loss to follow-up. It is assumed in this paper that censoring is independent of the health status process F,(.).
For reasons that will become clear, we often need to introduce an artificial ending point L before the trial termination. Accordingly, our definition of quality adjusted Lifetime changes to p Jo where Tf L = min(Tf, L). For notational simplicity, we still use Tf instead of Tf L throughout. Hence, we need to keep in mind that Tf now is a quantity that has a upper bound L.
In a typical clinical trial, we observe for the ith individual the random vectors
Our aim is to estimate the survival distribution of quality adjusted lifetime, S v {x) = pr(f7 > x) (x ^ 0), from such a sample.
THE ESTIMATOR AND ITS PROPERTIES
In developing the estimator for the survival function of quality adjusted lifetime U, we shall rely heavily on the counting process notation and the martingale theory for stochastic integrals as described by Fleming & Harrington (1991, Ch. 1) . First, we define the possibly censored quality adjusted life for the ith individual by UT= f GW(0}*-Jo A natural temptation is to estimate the survival function using the Kaplan-Meier estimator applied to the censored quality adjusted lifetime data: {Uf, Af} for i = 1,..., n, namely, (31) where N*{u) = X I{Uf < u, Af = 1), 7*(u) = I /(t/f ^ u).
As pointed out by Gelber et al. (1989) , this generally leads to biased estimation. One exception is when the quality of life function Q = 1, in which case U, = Tf, Uf = Xf and (31) gives the usual Kaplan-Meier estimator for the survival distribution of T*.
Instead we will use the method of weighted estimating equations similar to that proposed by Robins & Rotnitzky (1992) and Robins, Rotnitzky & Zhao (1994) . The motivation is as follows. With no censoring, the survival function S v {x) would be estimated straightforwardly using the empirical survival function § u (x) = n~1Y,I(U i >x).
Equivalently, S v {x) solves the estimating equation E {/(t// > x) -S v (x)} = 0. With censoring, we note that, for a fixed x, if U { exceeds x, then this would be known at any time s such that s~^sf(x), where Jo whereas U { will be known to be less than x only if
Therefore, with censoring, we would observe the value /([/; > x) if and only if C, > 7](x), where 7](x) = min {Tf, sf (x)}. Consequently, the indicator for a complete observation with respect to x can be denned as A,(x) = /{C,> 7](x)}. A typical individual whose health status would be observed until 7J(x) would have probability K{T t (x)} of not being censored, where K(u) -pr(C > u). Since censoring is independent of health status, an individual with a health history uncensored and observed up to T t (x) is on average representative of l/K{T t (x)} similar individuals some of which may be censored. This suggests using the weighted estimating equation
Henceforth we shall take x to be fixed. For ease of notation, we will use T { in place of 7](x) and A,-in place of A,(x). That the estimating equation is unbiased can be seen as follows:
Since K(t) is unknown, we propose to estimate it using the Kaplan-Meier estimator for the censoring random variable C. That is, with data where
Like T t and A,, K(t) is a function of x. Since E A,/^(7^) = n as long as the largest observation is not censored, we obtain, after substituting £(7}) for K(T t ) in (3-2), Remark 1. In the special case where U { = T*, that is quality of life function Q is equal to one for all health states, then S^x) = S*(x).
Remark 2. The use of the artificial ending point L, and T* L = min(L, T*) in place of T*, is to ensure that the largest observation is indeed uncensored.
The Appendix gives a representation of our weighted estimator as a stochastic integral of a counting process martingale. This will enable us to use the theory of counting processes, as described by Fleming & Harrington (1991, Ch. 5) , to prove that our estimator is consistent and asymptotically normal, and that the asymptotic variance of n i {S u (x) -S u (x)} can be estimated by
where and §(u) corresponds to the Kaplan-Meier estimator for S(u) -pr(T> u).
SIMULATION RESULTS
In order to evaluate the behaviour of our estimator, we report two simulation experiments to compare our estimator with the true survival distribution and the Kaplan-Meier estimator. In the first example, we are concerned with a simple case, such as time without symptoms of disease and toxicity, where only one health state has a quality of life function equal to one and all other health states have quality of life equal to zero. The second example deals with the more general setting where more than one health state contributes to quality adjusted life, the so-called quality adjusted time without symptoms of disease and toxicity. For demonstration purposes, we use only two health states here, though our formula applies for more complex health histories. In both cases, we compare our estimator with the true underlying distribution, and our variance estimate with the sample variance computed from simulation data.
In the first example, we replicate a simulation experiment conducted by Gelber et al. (1989) . In this study, 100 censored health status data are used to estimate the survival distribution of time without symptoms of disease and toxicity. It is assumed that the time of toxicity 'TOX' follows a uniform distribution on [0, TOX2] ([0, 72]), time to relapse 'TR' follows an exponential distribution with hazard X = Y25, and follow-up *FU' is uniform on [48, 96] . All these random variables are generated independently, even though it is not required that 'TOX' be independent of 'TR' in order to use our formula. The goal is to estimate the survival distribution of time without symptoms of disease or toxicity after L = 80 weeks on study. The true underlying survival function for time without symptoms of disease and toxicity is given by Gelber et al. (1989) ,
Our estimator is computed from equation (3-3). Here
Ti-min(sf(x), TRf}, sf(x) = TOX,+ x, TRf = min(TR,, L), FU,), t/,= 7J-TOX, and £(7j) is the Kaplan-Meier estimator of the censoring variable at time T t . The variance estimate is obtained from (3-4) accordingly. We also calculate the naive Kaplan-Meier estimator according to (31).
In Fig. l(a) , comparisons are made on the true survival distribution of time without symptoms of disease and toxicity calculated from (41), the average over 2000 simulations of the Kaplan-Meier estimator, and the average over 2000 simulations of our proposed weighted estimator. Our weighted estimator performs well, too close to the true distribution to distinguish them from the plot. As expected, the Kaplan-Meier estimator is biased. In Fig. l(b) we compare the empirical sample variance of our estimator over the 2000 simulations to the average of the estimated variance given by (3-4). The average of our variance estimates is very close to the empirical sample variance of our estimator. In the second example with two health states, the random variables are generated the same way as in the first example. Quality of life in the toxicity period is now assigned a value of 0-5. We wish to estimate the distribution of quality adjusted time without symptoms of disease and toxicity after L = 80 weeks on study. The true survival distribution is
Our estimator for this distribution and the estimate of its variance can be obtained from equations (3-3) and (3-4).
Figure 2(a) shows the average of our estimator from 2000 simulations and, superimposed on it, the true distribution calculated from (4-2). Figure 2(b) shows the empirical sample variance of our estimator and the average of our variance estimate over 2000 simulations. Again, these estimators perform very well.
DISCUSSION
When we first considered the problem of estimating the distribution of quality adjusted lifetime using a weighted estimator of the complete observations, we originally defined a complete observation as any individual whose complete heath history was uncensored; that is C t >Tf. Thus a naive weighted estimator for S v (x) would be defined as n~' EAf/(£/,>*)/.£( Tf), where Af = I{C,>Tf). This estimator is also consistent and asymptotically normal. We realised when estimating S v (x), for a fixed x, that by redefining a complete observation to be x dependent, as in § 3, the number of individuals defined as complete observations increased. Consequently, the efficiency of the estimator improved, in some cases as much as two-fold. Further improvement of the efficiency of estimators for quality adjusted lifetime will be the subject of future research.
One caution is that, Like the Kaplan-Meier estimator and Greenwood's formula for its variance, the survival estimate is unstable near the tails of the distribution when there is much censoring. The first term in (A-l) is an average of n independent, identically distributed random variables with mean zero and finite variance. By the Law of Large Numbers, this term converges to zero in probability. Since, by assumption, T < ^ L (i = 1,..., ri), where the constant L is such that K(L) > 0, the remaining term in (A-l) is bounded from above by
Since &{u) converges uniformly to the survival distribution K(u) for u ^ L (Fleming & Harrington, 1991, Ch. 6 ), this implies that (A-2) converges to zero in probability. Thus both terms in (A-l) converge to zero in probability, implying that § v (x) is a consistent estimator of S v (x). Next we investigate the asymptotic distribution of n*{S[/(x) -Su(x)}. According to (3-3), we can write
Letting X c {u) denote the hazard function for the censoring distribution, we define a filtration #"(u) as the increasing sequence of cr-algebras generated by <T{/(C, < x), x < u; V t (s), 0 < s < oo, i = 1,..., n).
That is, &(u) defines all the health status information for all time and the information for the censoring variables that is observed within time unit u. The corresponding martingale process M\(u) can be expressed as where §(u) corresponds to the Kaplan-Meier estimator for S{u) = pr(T> u). In view of equalities (A-4), (A-5), (A-6), and, since T, < L, for i = 1,..., n, (A-3) becomes n*{S v (x) -S^x)} = n~* X {B( -M*)} -n~* £ -7^ {B, -G(B, «)}, (A B, u) , is given by which converges to G(B, u) = £{B ( /(7; ^ u)}/S(u) in probabihty. From the central limit theorem, the first term in (A-8) goes to a normal distribution with mean zero and variance
S v (x){l-S v {x)}.
(A-9)
From the martingale central limit theorem (Fleming & Harrington, 1991, Ch. 5) , the second term in (A-8) also converges to a normal distribution with mean zero, and its variance is (A-10)
It is also clear that the first and second terms are uncorrelated, since B, is ^(0) measurable. The proof of asymptotic normality will be completed by demonstrating that all the other terms in (A-8) converge to zero in probability. First, because {G(B, u} -G*(B, u) } is an #"(u) predictable process, the third term in (A-8) converges in probability to zero as a consequence of Lenglart's Inequality (Lenglart, 1977) . Finally, the last term in (A-8) is also negligible, since S v (x) -S v (x) converges to zero in probability, and «-* T
Jo K(u)S(u~)
converges to a mean zero normal distribution by a simple application of the martingale central limit theorem.
Combining (A-9), (A-10) and the above arguments, we can claim that n*{St;(x) -Su(x)} goes to a normal distribution with mean zero and variance S 0 (x){l-S a {x) }+ [ ^S(u)G(B,u){l-G(B,u) )du.
jo Mm In practice we can estimate the above variance using ^(x) for S v (x), the Nelson estimator dN c (u)/Y(u) for l c (u) du, the Kaplan-Meier estimators £(u) and S(u) for K{u) and S(u), G\B, U) defined previously for G (B, u) , as well as the relationship of (A-6). The simplified form of the estimated variance is therefore S a (x){l - § v (x)} + n" 1 T j^-2 [6(B, u) {l -G(B, «)}].
